Beqvez® (fidanacogene elaparvovec-dzkt)
for Hemophilia

Beqvez (fidanacogene elaparvovec-dzkt) is a one-time gene therapy for adult males with moderate to severe hemophilia B. It delivers a high-activity factor IX gene to liver cells using a bio-engineered AAV, enhancing factor IX production to improve clotting and reduce bleeding risks. It is intended for patients on factor IX prophylaxis, those with a history of life-threatening bleeding, or those with recurrent serious bleeding episodes, provided they lack neutralizing antibodies to AAVRh74var capsid.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Hemophilia